Sugi Predict

Sugi Predict / Compounds / SCHEMBL3760367

SCHEMBL3760367

SCHEMBL3760367

CC(C)(C)OC(=O)NN(C(=O)N1CCCC1)c1cc[c]cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ CTSL P07711 3/20 0.36
▸ CTSB P07858 3/20 0.36
▸ CTSS P25774 2/20 0.36
▸ CTSD P07339 1/20 0.36
▸ ABL1 P00519 1/20 0.35
▸ RIN1 Q13671 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ AKT1 P31749 2/20 0.33
▸ GPR119 Q8TDV5 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CTSK P43235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760364 0.80 AKT1 (0.36) MEN1KMT2ACTSLCTSBCTSS
SCHEMBL3763750 0.77 MAPT (0.38) MEN1KMT2AABL1RIN1MAPT
SCHEMBL3765360 0.69 SMN1; SMN2 (0.41) MEN1KMT2AMAPTNPC1HTT
SCHEMBL16161817 0.68 ALDH1A1 (0.44) MEN1KMT2AMAPTHTTHPGD
SCHEMBL3760646 0.68 HPGD (0.36) MAPTNPC1HTTRAB9AHPGD
SCHEMBL11947540 0.67 DRD2 (0.38) MAPTAKT1
SCHEMBL3759117 0.65 ALDH1A1 (0.69) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL10565579 0.65 AKT1 (0.49) MEN1KMT2ACTSLCTSBCTSS
SCHEMBL22590 0.65 CYP17A1 (0.50) SMN1; SMN2L3MBTL1
SCHEMBL28420950 0.64 MIF (0.46) CTSLCTSBCTSSMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 — — EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 — — US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 — — EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MEN1 2762/4885KMT2A 2175/4885CTSL 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.